The Claim
Following discontinuation of liraglutide therapy in adults with MASLD without type 2 diabetes, circulating levels of MMP-10, IL10RB, FGF-23, and Flt3L increase significantly, whereas no significant changes in these biomarkers occur after withdrawal of lifestyle intervention.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with MASLD but without type 2 diabetes, stopping liraglutide causes measurable increases in four specific blood biomarkers linked to inflammation and metabolism, while stopping lifestyle changes does not produce these changes.
See the scientific wording
After discontinuation of liraglutide therapy in adults with MASLD without type 2 diabetes, circulating levels of MMP-10, IL10RB, FGF-23, and Flt3L increase significantly, while no such changes occur after lifestyle intervention withdrawal, suggesting a unique proinflammatory metabolic signature following pharmacological cessation.
When GLP-1 receptor signaling stops, fat tissue becomes dysfunctional and releases inflammatory proteins into the blood, which include MMP-10, IL10RB, FGF-23, and Flt3L. This happens because the fat cells lose a key regulatory signal that keeps their genes and metabolism stable, leading to a cascade of stress responses that activate immune pathways.
What the research says
1 studyWhen people with fatty liver disease stop taking liraglutide, their bodies release more inflammatory proteins—something that doesn’t happen when they stop dieting. This suggests the drug’s sudden stop sends a unique stress signal to the body.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.